Bengaluru-based biotechnology startup, CrisprBits Private Limited, has inaugurated a CRISPR gene editing and diagnostics ...

In a world grappling with an ever-evolving geopolitical crisis, fostering cross-pollination of ideas, research, and policies ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

Colossal, a leading biosciences company working to combat environmental dangers and revive extinct species, has reached a new ...

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends lifespan by about 50 percent in a mouse model of the fatal ...

Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu ...

Researchers have developed a gene-editing treatment for prion disease that extends lifespan by about 50 percent in a mouse model of the fatal neurodegenerative condition. The treatment, which uses ...

The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...

Editas Medicine ( (EDIT) ) has provided an announcement. Editas Medicine announced new in vivo preclinical proof of concept data and outlined its strategic priorities and key milestones for 2025, ...

Orna Therapeutics and Vertex will use lipid nanoparticle system to develop gene-editing therapies for people with SCD and TDT ...

CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced that the Company’s ...